All In Biotech

Drug Trial Radar · NCT06090539

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 460 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

460

Planned (sponsor's estimate)

Start

Dec 29, 2023

Primary completion

Oct 28, 2027

Study completion Oct 28, 2028

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.

Conditions

  • Relapsed/Refractory Non-Hodgkin Lymphoma

Interventions

  • BMS-986458Drug

    Specified dose on specified days.

  • RituximabDrug

    Specified dose on specified days.

  • Glofitamab/ObinutuzumabDrug

    Specified dose on specified days

  • MosunetuzumabDrug

    Specified dose on specified days

  • EpcoritamabDrug

    Specified dose on specified days

  • GolcadomideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to 2 years and 1 month
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to 2 years and 1 month
  3. Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteriaTime frame: Up to Day 28
  4. Number of participants with AEs leading to deathTime frame: Up to 2 years and 1 month
  5. Number of participants with AEs leading to discontinuationTime frame: Up to 2 years and 1 month
  6. Number of participants with a complete response rate (CRR) according to the Lugano response criteria for Non-Hodgkin Lymphoma by Investigator assessmentTime frame: Up to 2 years and 11 month

Locations

76 sites in 15 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona - Phoenix

    Phoenix, Arizona · Recruiting

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • Local Institution - 0068

    Jacksonville, Florida · Not yet recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Mayo Clinic in Rochester, Minnesota

    Rochester, Minnesota · Recruiting

  • Local Institution - 0124

    Omaha, Nebraska · Not yet recruiting

  • Local Institution - 0047

    Lake Success, New York · Completed

  • Local Institution - 0037

    New York, New York · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Local Institution - 0045

    Providence, Rhode Island · Not yet recruiting

  • Local Institution - 0118

    Antofagasta, AN, Chile · Not yet recruiting

  • Local Institution - 0105

    Santiago, Metropolitana de Santiago, Chile · Not yet recruiting

  • Local Institution - 0109

    Santiago, Santiago Metropolitan, Chile · Not yet recruiting

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Local Institution - 0087

    Zhengzhou, Henan, China · Not yet recruiting

  • Local Institution - 0120

    Suzhou, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Local Institution - 0130

    Nanchang, Jiangxi, China · Not yet recruiting

  • Local Institution - 0129

    Shenyang, Liaoning, China · Not yet recruiting

  • Local Institution - 0132

    Qingdao, Shandong, China · Not yet recruiting

  • Local Institution - 0131

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Local Institution - 0128

    Hangzhou, Zhejiang, China · Not yet recruiting

  • CHU SAINT ELOI - Departement Hematologie Clinique

    Montpellier, France · Recruiting

  • Hôpital Saint-Louis

    Paris, France · Recruiting

  • Institut Claudius Regaud

    Toulouse, France · Recruiting

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, Aquitaine, France · Recruiting

  • Local Institution - 0125

    Lyon, Nan, France · Not yet recruiting

  • Hopital Claude Huriez - CHU de Lille

    Lille, Nord, France · Recruiting

  • Gustave Roussy

    Villejuif, Paris, France · Recruiting

  • Henri Mondor Hospital

    Créteil, Val-de-Marne, France · Recruiting

  • Helios Klinikum Berlin-Buch

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Essen

    Essen, Germany · Recruiting

  • Universitätsklinikum Münster - Albert Schweitzer Campus

    Münster, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinikum des Saarlandes

    Homburg, Saarland, Germany · Recruiting

  • Universitätsklinikum Leipzig

    Leipzig, Saxony, Germany · Recruiting

  • Local Institution - 0107

    Athens, Greece · Not yet recruiting

  • Local Institution - 0102

    Athens, Greece · Not yet recruiting

  • Local Institution - 0103

    Pátrai, Achaḯa, Greece · Not yet recruiting

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.